Discovery and validation of peritoneal endometriosis biomarkers in peritoneal fluid and serum

See Ling Loy, Zhou J, Jieliang Zhou, Liang Cui, Cui L, Cui Liang, Tan TY, Tse Yeun Tan, Tat Xin Ee, Ee TX, Bernard Su Min Chern, Chern BSM, Jerry Kok Yen Chan, Lee YH, Yie Hou Lee
Reproductive BioMedicine Online · 2021 · vol. 43(4) , pp. 727–737 · doi:10.1016/j.rbmo.2021.07.002 · PMID:34446375 · W3179495136
article OA: closed CC0 ⤵ 12 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Researchers identified and validated novel biomarkers for peritoneal endometriosis in both peritoneal fluid and serum samples.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Research questionWhat are the potential biomarkers for peritoneal endometriosis in peritoneal fluid and serum?DesignCase-control studies composed of independent discovery and validation sets were conducted. In the discovery set, untargeted liquid chromatography-mass spectrometry (LC-MS/MS) metabolomics, multivariable and univariable analyses were conducted to generate global metabolomic profiles of peritoneal fluid for endometriosis and to identify potential metabolites that could distinguish peritoneal endometriosis (n = 10) from controls (n = 31). The identified metabolites from the discovery set were validated in independent peritoneal fluid (n =19 peritoneal endometriosis and n = 20 controls) and serum samples (n = 16 peritoneal endometriosis and n = 19 controls) using targeted metabolomics. The area under the receiver-operating characteristics curve (AUC) analysis was used to evaluate the diagnostic performance of peritoneal endometriosis metabolites.ResultsIn the discovery set, peritoneal fluid phosphatidylcholine (34:3) and phenylalanyl-isoleucine were significantly increased in peritoneal endometriosis groups compared with control groups, with AUC 0.77 (95% CI 0.61 to 0.92; P = 0.018) and AUC 0.98 (95% CI 0.95 to 1.02; P < 0.001), respectively. In the validation set, phenylalanyl-isoleucine retained discriminatory performance to distinguish peritoneal endometriosis from controls in both peritoneal fluid (AUC 0.77, 95% CI 0.61 to 0.92; P = 0.006) and serum samples (AUC 0.81, 95% CI 0.64 to 0.99; P = 0.004), with notably stronger discrimination between peritoneal endometriosis and controls in proliferative phase.ConclusionOur preliminary results propose phenylalanyl-isoleucine as a potential biomarker of peritoneal endometriosis, which may be used as a minimally invasive diagnostic biomarker of peritoneal endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Ascitic Fluid Endometriosis Peritoneal Diseases Adult Ascitic Fluid Biomarkers Biomarkers Case-Control Studies Endometriosis Female Humans Metabolome Metabolomics Metabolomics Peritoneal Diseases Pilot Projects

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (54)

Cited by (14)

Source provenance

europepmc
last seen: 2026-08-02T06:10:09.037253+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:24:20.309598+00:00
License: CC0 · commercial use OK